|1.||Scheithauer, W: 8 articles (06/2003 - 08/2000)|
|2.||Avallone, A: 7 articles (06/2006 - 04/2000)|
|3.||Comella, P: 7 articles (06/2006 - 04/2000)|
|4.||Raderer, M: 7 articles (06/2003 - 08/2000)|
|5.||Depisch, D: 6 articles (06/2003 - 04/2001)|
|6.||Comella, G: 6 articles (06/2002 - 04/2000)|
|7.||Valentini, Vincenzo: 5 articles (10/2012 - 09/2004)|
|8.||Kornek, G V: 5 articles (06/2003 - 04/2001)|
|9.||Ulrich-Pur, H: 5 articles (04/2003 - 04/2001)|
|10.||Cellini, Numa: 4 articles (10/2012 - 09/2004)|
|1.||Colorectal Neoplasms (Colorectal Cancer)
04/01/2003 - "Raltitrexed has proven efficacy in the treatment of advanced colorectal cancer and has an acceptable toxicity profile. "
04/01/2014 - "An electronic search was undertaken to identify randomized controlled trials comparing raltitrexed-based regimen to 5-fluorouracil-based regimen in patients with advanced colorectal cancer. "
06/01/2002 - "Ralitrexed (Tomudex) or Nordic-FLv regimen in metastatic colorectal cancer: a randomized phase II study focusing on quality of life, patients' preferences and health economics."
06/01/2002 - "The objective of this study was to analyse the efficacy and tolerance of raltitrexed in elderly patients with advanced colorectal cancer. "
03/01/2002 - "Data are analysed from four phase III and five phase II studies including over 1300 patients with advanced colorectal cancer, some of whom were elderly or received higher doses of raltitrexed. "
10/01/2011 - "Raltitrexed in mesothelioma."
04/01/2002 - "This review outlines the appropriate management of patients treated with raltitrexed, whether as monotherapy or in combination, and discusses the preliminary results of combination studies with raltitrexed in a range of tumour types including advanced CRC, malignant mesothelioma, gastric, pancreatic, head and neck, and non-small-cell lung cancers. "
12/20/2007 - "A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma."
06/01/2005 - "Within a single-institution phase II trial, we investigated the antitumor activity of the Raltitrexed-Oxaliplatin combination as second-line therapy for malignant pleural mesothelioma (MPM). "
01/15/2003 - "Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study."
10/15/1991 - "ICI D1694 cured the L1210:ICR ascitic tumor in mice at 0.4 mg/kg daily for 5 days (maximum tolerated dose, approximately 50 mg/kg).(ABSTRACT TRUNCATED AT 400 WORDS)"
01/01/1991 - "Current studies with 3H-ICI D1694 are aimed at demonstrating metabolism to polyglutamates in tumor cells. "
09/01/2004 - "The use of raltitrexed in a neoadjuvant chemoradiation schedule promoted high pathologic tumor downstaging and use of a sphincter-saving procedure. "
04/01/2004 - "A population pharmacokinetic model has been developed for raltitrexed in patients with advanced cancer. "
09/01/1999 - "Fifty patients with advanced solid tumors and good performance status were treated with raltitrexed as a 15-min i.v. infusion every 3 weeks, at doses escalating from 0.6 to 4.5 mg/m2. "
|4.||Rectal Neoplasms (Rectal Cancer)
05/01/2006 - "Pre-operative radiochemotherapy with raltitrexed for resectable locally-advanced rectal cancer: a phase II study."
11/01/2005 - "The aim of this prospective multicenter phase II study was to evaluate the feasibility, gastrointestinal and hematological acute toxicity of raltitrexed in combination with radiotherapy in rectal cancer patients. "
04/01/2003 - "The aim of this phase I study was to determine the recommended dose of raltitrexed in combination with radiotherapy in patients with unresectable/recurrent rectal cancer. "
04/01/2003 - "Raltitrexed plus radiotherapy for the treatment of unresectable/recurrent rectal cancer: a phase I study."
08/01/2000 - "This study demonstrates that raltitrexed can be combined with postoperative radiotherapy for treatment of patients with Dukes' stage B or C rectal cancer. "
01/01/2005 - "Forty-six patients with advanced, histologically proven pancreatic (n = 37, 80.4%) or biliary (n = 9, 19.6%) carcinoma received 3 mg/m2 raltitrexed intravenously once every 3 weeks. "
11/01/2003 - "On the other hand, raltitrexed showed no influence on DPD activity in MIAPaCa2 pancreatic carcinoma cells. "
12/01/2000 - "Human ileocecal carcinoma cells (HCT-8) were followed up to 11 days in vitro after a 2-h exposure to 1 microM raltitrexed (IC(95)) in a time-lapse video system. "
09/01/2004 - "Between 1998 and 2002, 54 consecutive patients with Stage T3 or T2N+ resectable rectal carcinoma were treated with preoperative chemoradiation, i.v. bolus of raltitrexed on Days 1, 19, and 38 and concurrent 50 Gy external beam radiotherapy. "
09/01/1998 - "A concentration of 1 microM Tomudex decreased the shoulder of the radiation survival curves for normally oxygenated and hypoxic human HT-29 colon carcinoma cells and human SCC-25 head and neck squamous carcinoma cells, resulting in enhancement ratios of 10 and 2.8 for normally oxygenated and hypoxic HT-29 cells at 5 Gray, respectively, and enhancement ratios of 19.5 and 2.7 for normally oxygenated and hypoxic SCC-25 cell at 5 Gray, respectively. "
|1.||raltitrexed (D 1694)
|4.||Leucovorin (Folinic Acid)
|1.||Drug Therapy (Chemotherapy)
|3.||Combination Drug Therapy (Combination Chemotherapy)
|5.||Heterologous Transplantation (Xenotransplantation)